ARK Genomic Revolution ETF (BATS:ARKG) Reaches New 52-Week High – Still a Buy?

ARK Genomic Revolution ETF (BATS:ARKG) hit a new 52-week high during trading on Monday . The company traded as high as $42.34 and last traded at $42.08, with a volume of 655870 shares changing hands. The stock had previously closed at $41.43.

ARK Genomic Revolution ETF Trading Down 0.7%

The firm has a 50-day simple moving average of $32.86 and a two-hundred day simple moving average of $30.49.

Hedge Funds Weigh In On ARK Genomic Revolution ETF

A number of hedge funds have recently bought and sold shares of ARKG. SG Americas Securities LLC raised its stake in ARK Genomic Revolution ETF by 207.8% in the fourth quarter. SG Americas Securities LLC now owns 102,521 shares of the company’s stock valued at $2,970,000 after purchasing an additional 69,215 shares in the last quarter. Canal Insurance CO bought a new position in ARK Genomic Revolution ETF in the 4th quarter valued at about $3,476,000. Cresset Asset Management LLC raised its position in shares of ARK Genomic Revolution ETF by 55.9% in the 3rd quarter. Cresset Asset Management LLC now owns 121,062 shares of the company’s stock valued at $3,362,000 after buying an additional 43,403 shares in the last quarter. Kingsview Wealth Management LLC acquired a new position in shares of ARK Genomic Revolution ETF in the 4th quarter valued at approximately $5,975,000. Finally, DLD Asset Management LP bought a new stake in shares of ARK Genomic Revolution ETF during the 3rd quarter worth approximately $1,509,000.

About ARK Genomic Revolution ETF

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.